EA202193338A1 - Терапевтические композиции, включающие дейтерированные или частично дейтерированные соединения n,n-диметилтриптамина - Google Patents

Терапевтические композиции, включающие дейтерированные или частично дейтерированные соединения n,n-диметилтриптамина

Info

Publication number
EA202193338A1
EA202193338A1 EA202193338A EA202193338A EA202193338A1 EA 202193338 A1 EA202193338 A1 EA 202193338A1 EA 202193338 A EA202193338 A EA 202193338A EA 202193338 A EA202193338 A EA 202193338A EA 202193338 A1 EA202193338 A1 EA 202193338A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dimethyltryptamine
deuterated
partially
present
therapeutic compositions
Prior art date
Application number
EA202193338A
Other languages
English (en)
Inventor
Питер Рэндс
Зела Джоэл
Тиффани Бенвэй
Original Assignee
Смол Фарма Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смол Фарма Лтд filed Critical Смол Фарма Лтд
Publication of EA202193338A1 publication Critical patent/EA202193338A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

Настоящее изобретение относится к композициям, содержащим N,N-диметилтриптамин, дейтерированный N,N-диметилтриптамин и/или частично дейтерированный N,N-диметилтриптамин. В частности, настоящее изобретение относится к композициям, содержащим комбинацию N,N-диметилтриптамина и 2% или более по массе одного или нескольких дейтерированных соединений N,N-диметилтриптамина, выбранных из ,-дидейтеро-N,N-диметилтриптамина и ,,,-тетрадейтеро-N,N-диметилтриптамина. Дополнительные и альтернативные композиции по настоящему изобретению содержат комбинацию N,N-диметилтриптамина и 2% или более по массе одного или нескольких частично дейтерированных соединений N,N-диметилтриптамина, выбранных из ,,-тридейтеро-N,N-диметилтриптамина, ,-дидейтеро-N,N-диметилтриптамина и -дейтеро-N,N-диметилтриптамина. Также представлены способы синтеза композиций по настоящему изобретению и способы применения описанных здесь композиций для лечения психиатрических или психокогнитивных расстройств, таких как большое депрессивное расстройство.
EA202193338A 2019-06-03 2020-06-02 Терапевтические композиции, включающие дейтерированные или частично дейтерированные соединения n,n-диметилтриптамина EA202193338A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1907871.6A GB201907871D0 (en) 2019-06-03 2019-06-03 Therapeutic compositions
PCT/EP2020/065244 WO2020245133A1 (en) 2019-06-03 2020-06-02 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds

Publications (1)

Publication Number Publication Date
EA202193338A1 true EA202193338A1 (ru) 2022-03-02

Family

ID=67385960

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193338A EA202193338A1 (ru) 2019-06-03 2020-06-02 Терапевтические композиции, включающие дейтерированные или частично дейтерированные соединения n,n-диметилтриптамина

Country Status (20)

Country Link
US (2) US11771681B2 (ru)
EP (2) EP4062910A1 (ru)
JP (1) JP2022535093A (ru)
KR (1) KR20220034061A (ru)
CN (1) CN114096246A (ru)
AU (1) AU2020286709A1 (ru)
BR (1) BR112021024333A2 (ru)
CA (2) CA3142290A1 (ru)
DK (1) DK3826632T3 (ru)
EA (1) EA202193338A1 (ru)
ES (1) ES2922101T3 (ru)
GB (4) GB201907871D0 (ru)
HR (1) HRP20220837T8 (ru)
HU (1) HUE059439T2 (ru)
IL (1) IL288617A (ru)
MX (1) MX2021014728A (ru)
PL (1) PL3826632T3 (ru)
PT (1) PT3826632T (ru)
TW (1) TW202210075A (ru)
WO (1) WO2020245133A1 (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
HUE059403T2 (hu) * 2019-11-07 2022-11-28 Small Pharma Ltd Vegyületek
CN115380028A (zh) 2020-02-04 2022-11-22 明德赛特制药公司 用于治疗cns病症的作为血清素能致幻剂的3-吡咯烷-吲哚衍生物
CN115974757A (zh) 2020-02-04 2023-04-18 明德赛特制药公司 用于治疗cns病症的作为血清素能致幻剂的赛洛辛衍生物
AU2021276656A1 (en) 2020-05-19 2022-11-24 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
GB2605144A (en) * 2021-03-22 2022-09-28 Small Pharma Ltd Deuterated compounds
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
MX2022014900A (es) * 2020-06-02 2023-03-27 Small Pharma Ltd Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada.
EP3902541B1 (en) * 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
US20210378969A1 (en) 2020-06-02 2021-12-09 Small Pharma Ltd. Therapeutic solid dosage forms
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
TW202237565A (zh) 2020-12-01 2022-10-01 英商小藥業有限公司 氘化化合物
AU2021390543A1 (en) 2020-12-03 2023-06-22 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
CA3210270A1 (en) * 2021-03-02 2022-09-09 Abdelmalik Slassi Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
CN117320711A (zh) * 2021-04-26 2023-12-29 阿泰治疗公司 新型n,n-二甲基色胺组合物和方法
CA3217559A1 (en) * 2021-05-05 2022-11-10 Kamaluddin Abdur-Rashid Catalytic tryptamine processes and precursors
KR20240009433A (ko) * 2021-05-17 2024-01-22 사이빈 아이알엘 리미티드 실로시빈의 제형
AU2022287013A1 (en) * 2021-06-02 2023-12-07 Compass Pathfinder Ltd. Fluorinated tryptamine compounds, analogues thereof, and methods using same
AU2022328217A1 (en) 2021-08-12 2024-03-14 Kuleon Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
CA3229907A1 (en) * 2021-08-23 2023-03-02 Nicholas COZZI Deuterated empathogens
CA3229910A1 (en) * 2021-08-23 2023-03-02 Alexander Shulgin Research Institute, Inc. Fluorinated empathogens
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159201A1 (en) * 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
EP4159192A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
WO2023076135A1 (en) * 2021-10-29 2023-05-04 Psilera Inc. N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same
WO2023089132A1 (en) 2021-11-18 2023-05-25 Small Pharma Ltd Injectable and inhalable formulations
WO2023186867A1 (en) * 2022-03-31 2023-10-05 Cybin Irl Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336378A (en) 1980-04-10 1982-06-22 Sandoz, Inc. Isoxazolyl indolamines
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
AU2001266896B2 (en) 2000-06-16 2006-04-06 Jagotec Ag Improved injectable dispersions of propofol
WO2004085392A1 (en) 2003-03-25 2004-10-07 Faust Pharmaceuticals Melatonin derivatives and their use for treating neurological dysfunctions
CN101687788A (zh) 2006-10-19 2010-03-31 奥斯拜客斯制药有限公司 取代的吲哚
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
US20090076121A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched sumatriptan
WO2009049030A1 (en) 2007-10-09 2009-04-16 Triton Biopharma, Llc Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter
CA3052974A1 (en) 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
WO2019081764A1 (en) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS
WO2019089902A1 (en) 2017-11-01 2019-05-09 Drexel University Compounds, compositions, and methods for treating diseases
EA202192318A1 (ru) 2019-02-22 2021-12-21 Гх Рисерч Айрленд Лимитед 5-метокси-n,n-диметилтриптамин (5-meo-dmt) для лечения депрессии
JP2022522659A (ja) 2019-02-22 2022-04-20 ジーエイチ リサーチ アイルランド リミテッド 精神障害の処置における使用のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン（５－ｍｅｏ－ｄｍｔ）を含む組成物
BR112021016620A2 (pt) 2019-02-27 2021-11-03 Univ California Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
CA3130767A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
HUE059403T2 (hu) 2019-11-07 2022-11-28 Small Pharma Ltd Vegyületek
CN115974757A (zh) 2020-02-04 2023-04-18 明德赛特制药公司 用于治疗cns病症的作为血清素能致幻剂的赛洛辛衍生物
AU2021276656A1 (en) 2020-05-19 2022-11-24 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
WO2021234608A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
EP3902541B1 (en) 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
US20210378969A1 (en) 2020-06-02 2021-12-09 Small Pharma Ltd. Therapeutic solid dosage forms
GB202008961D0 (en) 2020-06-12 2020-07-29 Beckley Psytech Ltd Pharmaceutical composition
BR112023001967A2 (pt) 2020-08-05 2023-02-28 Univ Basel Método para induzir um estado psicodélico em um indivíduo, método para induzir um estado psicodélico em um indivíduo com segurança, método para fornecer um tratamento psicodélico de curta duração, método para determinar uma dose de dmt para um indivíduo, método para terapia e método para ajustar um estado psicodélico em um indivíduo em tempo real
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
CN115701994B (zh) 2020-08-28 2024-03-08 赛本英国有限公司 可注射制剂
US20220062237A1 (en) 2020-08-28 2022-03-03 Small Pharma Ltd Injectable formulation
CA3194558A1 (en) 2020-10-02 2022-04-07 Brett J. GREENE Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof

Also Published As

Publication number Publication date
CA3104072A1 (en) 2021-06-28
AU2020286709A1 (en) 2022-01-06
GB2585978B (en) 2021-07-14
GB2586940B (en) 2023-07-05
EP3826632A1 (en) 2021-06-02
EP3826632B1 (en) 2022-05-18
GB2586940A (en) 2021-03-10
HUE059439T2 (hu) 2022-11-28
CA3142290A1 (en) 2020-12-10
HRP20220837T8 (hr) 2023-02-03
EP4062910A1 (en) 2022-09-28
GB2585978A (en) 2021-01-27
IL288617A (en) 2022-02-01
US20200390746A1 (en) 2020-12-17
HRP20220837T1 (hr) 2022-10-14
TW202210075A (zh) 2022-03-16
ES2922101T3 (es) 2022-09-08
PL3826632T3 (pl) 2022-08-01
GB202107702D0 (en) 2021-07-14
GB2592822A (en) 2021-09-08
GB2592822B (en) 2023-07-05
GB201907871D0 (en) 2019-07-17
JP2022535093A (ja) 2022-08-04
BR112021024333A2 (pt) 2022-02-08
CN114096246A (zh) 2022-02-25
CA3104072C (en) 2022-07-19
US20220168275A1 (en) 2022-06-02
GB202008303D0 (en) 2020-07-15
MX2021014728A (es) 2022-03-11
KR20220034061A (ko) 2022-03-17
DK3826632T3 (da) 2022-07-11
US11771681B2 (en) 2023-10-03
GB202100807D0 (en) 2021-03-10
PT3826632T (pt) 2022-07-11
WO2020245133A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
EA202193338A1 (ru) Терапевтические композиции, включающие дейтерированные или частично дейтерированные соединения n,n-диметилтриптамина
MX2022005399A (es) Compuestos.
EA202092086A1 (ru) Ингибиторы аргиназы
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
PH12020552092A1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
MY196791A (en) New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions
EA201791829A1 (ru) Амидные соединения в качестве агонистов рецептора 5-ht
EA202290054A1 (ru) Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
PH12020551059A1 (en) Compounds for the treatment of kinase-dependent disorders
EA201992509A1 (ru) Гетероарилфениламинохинолины и аналоги
EA202090414A1 (ru) Соединения и их применение
MX2021010700A (es) Compuestos utiles en la terapia del vih.
MX2023005408A (es) Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina.
PH12020552172A1 (en) Cyclic dinucleotides as sting agonists
CY1114457T1 (el) Συνθεσεις που περιεχουν ενωσεις τεταρτοταγους αμμωνιου (quaternary ammonium)
EA202091340A1 (ru) Способ получения соединений "лекарственное средство-линкер"
MX2020008413A (es) Composiciones para la prevencion o tratamiento de la uveitis.
MX2019011558A (es) Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido).
PH12020551620A1 (en) Compositions for preventing or treating dry eye
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
MX2022005912A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria.
EA202090432A1 (ru) Новые соединения, активирующие путь nrf2